期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 64, 期 4, 页码 1930-1950出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.0c00932
关键词
-
资金
- NIH [R01CA193609, 1S10OD010678-01, 1S10RR026377-01, R01CA180519, 1R43CA246788-01, 1S10OD016226-01A1, R01CA240447]
- University of Tennessee College of Pharmacy Drug Discovery Center
- Rally
- CURE
The study reports a structurally optimized dual MDM2/XIAP inhibitor, leading to the discovery of a more potent analogue against EU-1, which exerts dual targeting effects and can induce cell death. The results suggest that the scaffold based on 14 shows promise for further development as a potential therapeutic agent for leukemia and other cancers.
Murine double minute 2 (MDM2) and X-linked inhibitor of apoptosis protein (XIAP) are important cell survival proteins in tumor cells. As a dual MDM2/XIAP inhibitor reported previously, compound MX69 has low potency with an IC50 value of 7.5 mu M against an acute lymphoblastic leukemia cell line EU-1. Herein, we report the structural optimization based on the MX69 scaffold, leading to the discovery of a 25-fold more potent analogue 14 (IC50 = 0.3 mu M against EU-1). We demonstrate that 14 maintains its mode of action by dual targeting of MDM2 and XIAP through inducing MDM2 protein degradation and inhibiting XIAP mRNA translation, respectively, which resulted in cancer cell growth inhibition and cell death. The results strongly suggest that the scaffold based on 14 is promising for further optimization to develop a new therapeutic agent for leukemia and possibly other cancers where MDM2 and XIAP are dysregulated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据